1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
Sosei Group said on December 24 that its partner Pfizer has nominated an oral small molecule targeting a G protein-coupled receptor (GPCR) associated with metabolic and other diseases as a clinical development candidate under their drug discovery collaboration deal. Sosei…
To read the full story
Related Article
- Third GPCR-Targeted Drug Enters Clinic under Sosei/Pfizer Collaboration
May 20, 2021
- 2nd GPCR-Targeted Candidate Enters Clinic under Sosei/Pfizer’s Drug Discovery Alliance
September 29, 2020
- Sosei Bags US$3 Million from Genentech on Nomination of New GPCR Disease Target
October 10, 2019
- Luring Big Pharma with GPCR Work, Sosei Heptares Treads Its Own Path to Pursue Small Molecule Targets
September 18, 2019
- Sosei, Takeda Seal Multi-Target Collaboration Deal
August 6, 2019
- Heptares Inks R&D Deal with Pfizer; Pfizer to Buy 3% Stake in Sosei for US$33 Million
December 2, 2015
BUSINESS
- Otsuka Achieves 2-Digit Growth Driven by Core Products
February 17, 2025
- Darzquro Filed for High-Risk Smoldering MM in Japan: J&J
February 17, 2025
- Nxera Founder Tamura to Bow Out from Board
February 17, 2025
- Kerendia Filed for Chronic Heart Failure in Japan: Bayer
February 17, 2025
- Takeda Files Liquid Formulation of IVIg Therapy in Japan
February 17, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…